knowledge -WSS

knowledge

author：knowledge 2025-08-12 09:08:49 - browse：7568

A glass office building of MassMutual with its sign on the top left — insurance coverage from STAT — Adobe

One of the country’s biggest life insurers is venturing into genetic testing, an area that’s historically been a minefield for that industry, in a purported effort to keep its members alive longer.

MassMutual announced Tuesday that it’s offering many of its 4.2 million policyholders free genetic risk assessments for eight common diseases, like heart disease, type 2 diabetes, and breast cancer. The Springfield, Mass.-based insurer hopes that when people learn they carry a genetic predisposition, they’ll take action to lower their risk through diet, exercise, and getting regular screenings.

Viewed one way, it’s a win-win: The longer its members live, the longer MassMutual can collect and invest their premiums without paying out.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： Indian pharmaceutical industry in denial over drug

WSS

NVIDIA and Google execs on the future of AI and drug discovery

Addiction experts warn against a second 'war on drugs'

'Stay indoors': Escaped wild animal on the loose in Berlin prompts urgent citywide search

Mass General totes up its waste in a move to tackle climate change

Big Tobacco's 'harm reduction': Is it for real, or a sham?

Readout Newsletter: Nvidia, Biogen, Ionis, AstraZeneca, ChatGPT

hotspot

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the financial innards of our health care system — by subscribing to STAT+.

focus

Sports medicine is finally prioritizing gender equality

Awakening the world to the whoosh: A patient's crusade

BioMarin wins approval for gene therapy to treat hemophilia A

Tocagen's brain cancer gene therapy trial continues. Investors worry

George Santos makes 1st court appearance after pleading not guilty to 13 counts

It's time to retire 'poor historian' from clinicians' vocabularies

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Study identifies new proteins linked to dementia risk 25 years later

Psychedelics group wrestles with new pharma identity

Arc Institute generative AI designs new CRISPR systems

entertainment

HIV vaccine remains elusive. Immunologists keep trying new ideas

Military medical care influenced by rank and race, new study finds

Public funding for King Charles III and royals has been recalculated due to windfarm deal profits

Tesla recalling nearly 16,000 of its 2021

Solving academic medical centers' existential crisis

Wife of Gilgo Beach murder suspect files for divorce, court filing shows

hotspot

knowledge

entertainment

hotspot